Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "Bipartisan House Bill Attempts to Limit FDA's HIT Oversight."

Following is an excerpt:

A bipartisan House bill introduced late Tuesday (Oct. 22) aims to clarify FDA's authority over health information technology by amending the Federal Food, Drug and Cosmetic Act so the agency will only regulate mobile medical applications that change the physiology of a patient and with little opportunity for human intervention. The move was applauded by industry and patient groups that see the bill as the first step in implementing a recommendation from a federal working group to re-focus FDA. ...

The Sensible Oversight for Technology which Advances Regulatory Efficiency (SOFTWARE) Act was introduced by Rep. Marsha Blackburn (R-TN) and co-sponsored by a bipartisan group of House lawmakers, including Republicans Phil Gingrey (GA) and Greg Walden (OR) as well as Democrats Diana DeGette (CO) and G.K. Butterfield (NC). The bill comes less than a month after FDA released finalized guidance for mobile medical applications that laid out a strategy of using enforcement discretion on low-risk devices. ...

However, Bradley Merrill Thompson, an attorney with Epstein, Becker and Green, took issue with the legislation's "piecemeal" approach, saying it could have adverse effects. He said while bipartisan support of health IT innovation is welcome, the lawmakers seem intent to follow the recommendation of the Bipartisan Policy Center and stratify health IT into three different layers -- administrative or non-clinical software; clinical software; and medical device software. There is an inherent challenge in trying to segment software when the development of software is going in the opposite direction, toward convergence, he said.

"The fact of the matter is that software operates like connective tissue holding together different parts of the health care system," Thompson said. "Thus, if we were to follow the lead of the technology, we would not try to separate out software into distinct bucket, but rather look for a more holistic way to approach software that creates large systems of care delivery."

He also raised concerns that the legislation was only "half done" since it does not explain how clinical and health software would be regulated, if not under FDA. The FDASIA workgroup was fairly clear in its recommendation that software in these categories would require regulation, said Thompson, who was a member of the workgroup. He highlighted computer-aided diagnosis, which takes X-rays and applies algorithms that identify abnormalities, as an example of why clinical software oversight was needed. Currently, the riskiest versions of the software are class III devices regulated by FDA, but the legislation would place the software in the category of clinical software, to be unregulated "until the future as of yet unspecified regulatory system is put in place." While the legislators appear to have reached consensus around the problem, they have not been able to develop a solution that would address such an outcome, he said.

"Personally, I would encourage them to continue their internal discussions to reach the point of a solution," Thompson said. "We should not approach this in a piecemeal fashion, first only agreeing as to somehow separating the types of software without completing the work to decide how the categories would, in fact, be regulated."

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.